en · de · es · fr · pt
faq-desk.peptides7250.com › Guide › Background And Molecular Design — Research Overview

Background And Molecular Design — Research Overview

By Editorial Desk · published 2025-08-16 · last reviewed 2025-09-18 · Guide

A practical reference on GRF(1-29): what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-09-18. Anything still debated is marked as such rather than presented as settled.

Background and Molecular Design

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

Background and Naming Conventions

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

Cjc-1295 at a glance

PropertyValueNotes
Molecular classSynthetic peptideAnalog of growth hormone-releasing hormone
Chain length29 amino acidsBased on the GRF(1-29) fragment
AppearanceWhite to off-white lyophilized powderCommon research supply form
SolubilitySoluble in water and aqueous buffersPowder requires reconstitution before use
Typical storage−20 °C or belowKept away from light and moisture

Mechanism and Pharmacokinetics

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

Related pages on this site

Persistence, Stability and Measurement

Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Receptor Action and Clearance

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Identity and Naming History

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Further detail

== History == Noom was founded in 2008 by friends Artem Petakov and Saeju Jeong. The company's mobile app officially launched in 2016. In 2019, Noom partnered with Novo Nordisk to offer one year of free access to its platform for patients prescribed the diabetes medication Saxenda. Noom reported $400 million in revenue in 2020. As of April 2021, the company stated it employed approximately 3,000 people, including 2,700 coaches. Petakov, a former software engineer at Google, currently leads Noom Ventures, while Jeong serves as Noom's Chairman. In 2023, Geoff Cook was appointed CEO of Noom. In 2024, Noom relocated its headquarters from New York City to Princeton, New Jersey.

Cinema Blend called it one of the most underappreciated games of the decade. In 2011, Official Xbox Magazine called it one of the ten PC franchises it wanted on the Xbox 360 console. In 2013, PC Gamer named it one of the 100 Best Horror Games on PC, and PCGamesN called it the seventh-best PC role-playing game. In 2014, Bloodlines was 90th in Empire's readers' poll of the 100 Greatest Video Games of All Time, and Maximum PC chose it as one of the games they wanted to be remastered for contemporary game systems. In 2015, Rock, Paper, Shotgun listed Bloodlines as the PC's 19th Best RPG and 15th Best Horror Game. In 2017, the game was listed 42nd on IGN's list of the Top 100 RPGs of all Time, Den of Geek named it one of the 20 Video Games that Deserve Remakes, and PC Gamer named it one of the best role-playing games of all time. In 2018, USGamer named it the 22nd best RPG of All Time, summarising that "for all of its bugs and questionable gameplay choices... the raw strength of its design still has the power to grab fans." PC Gamer highlighted the haunted "Ocean House Hotel" as a "high point of unexpected horror", comparing it to the Shalebridge Cradle level from Thief: Deadly Shadows (2004) and Ravenholm from Half-Life 2 (2004). In 2020, Rock, Paper, Shotgun named it the 44th-best RPG for PC.

Friedel-Crafts acylation of the n-butyl ether of thiophenol with benzoyl chloride gives the corresponding benzophenone. Reduction of the ketone with zinc/NaOH followed by treatment with HCl in ether affords the benzhydryl chloride. Displacement of the halogen with thiourea gives, by reaction of the last at its most nucleophilic center, the isothiouronium salt. Hydrolysis of the salt leads to the sulfur analog of a benzhydrol. Alkylation of the sodium salt of this last with N-(2-chloroethyl)dimethylamine affords captodiame.

It is not just heavy metals which can be toxic; other metals (for example beryllium and lithium) can be toxic too. Sleeping in a closed room with an electric fan running does not result in "fan death", as is widely believed in South Korea among older people. As of 2019, this belief was in decline. Nocturia (waking up at night to urinate) is equally prevalent in women and men, although it is more common among those over 50. Waking up a sleepwalker does not harm them. Sleepwalkers may be confused or disoriented for a short time after awakening, but the health risks associated with sleepwalking are from injury or insomnia, not from being awakened. Seizures cannot cause a person to swallow their own tongue, and it is dangerous to attempt to place a foreign object into a convulsing person's mouth. Instead it is recommended to gently lay a convulsing person on their side to minimize the risk of asphyxiation. Drowning is often inconspicuous to onlookers. In most cases, the instinctive drowning response prevents the victim from waving or yelling, which are therefore not dependable signs of trouble. Most drowning victims do not show prior evidence of distress. Herbal medicines are not necessarily safe and side-effect free; such medicines can have adverse effects. Human blood in veins is not actually blue. Blood is red due to the presence of hemoglobin; deoxygenated blood (in veins) has a deep red color, and oxygenated blood (in arteries) has a light cherry-red color.

Sources: en.wikipedia.org

Supporting material

=== In humans and other animals === Low levels of synephrine have been found in normal human urine, as well as in other mammalian tissue. To reduce the likelihood that the synephrine detected in urine had a dietary origin, the subjects tested by Ibrahim and co-workers abstained from the consumption of any citrus products for 48 hours prior to providing urine samples. A 2006 study of synephrine in human blood platelets by D'Andrea and co-workers showed increased levels in platelets from patients suffering from aura-associated migraine (0.72 ng/108 platelets, compared to 0.33 ng/108 platelets in control subjects). Earlier, the same research group had reported a normal human blood plasma level of synephrine of 0.90–13.69 ng/mL.

In an edition of the Ars Quatuor Coronatorum, the quarterly historical journal of the Quatuor Coronati Lodge, Masonic historian Robert Freke Gould verified the existence of a membership certificate issued by this Military Lodge. The document, 8.75 inches long and 8.5 inches wide, was a parchment sealed with a red wax seal, and tied with a yellow and blue ribbon. The membership certificate stated:

==== Removal of blood stains ==== Hydrogen peroxide reacts with blood as a bleaching agent, and so if a blood stain is fresh, or not too old, liberal application of hydrogen peroxide, if necessary in more than single application, will bleach the stain fully out. After about two minutes of the application, the blood should be firmly blotted out.

=== Mechanisms === Nicotinic acid reduces synthesis of low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), lipoprotein(a) and triglycerides, and increases high-density lipoprotein cholesterol (HDL-C). The lipid-therapeutic effects of nicotinic acid are partly mediated through the activation of G protein-coupled receptors, including hydroxycarboxylic acid receptor 2 (HCA2)and hydroxycarboxylic acid receptor 3 (HCA3), which are highly expressed in body fat. HCA2 and HCA3 inhibit cyclic adenosine monophosphate (cAMP) production and thus suppress the release of free fatty acids (FFAs) from body fat, reducing their availability to the liver to synthesize the blood-circulating lipids in question. A decrease in free fatty acids also suppresses liver expression of apolipoprotein C3 and PPARg coactivator-1b, thus increasing VLDL-C turnover and reducing its production. Nicotinic acid also directly inhibits the action of diacylglycerol O-acyltransferase 2 (DGAT2) a key enzyme for triglyceride synthesis. The mechanism behind nicotinic acid increasing HDL-C is not totally understood, but seems to occur in various ways. Nicotinic acid increases apolipoprotein A1 levels by inhibiting the breakdown of this protein, which is a component of HDL particles. It also inhibits HDL-C hepatic uptake by suppressing production of the cholesterol ester transfer protein (CETP) gene. It stimulates the ABCA1 transporter in monocytes and macrophages and upregulates peroxisome proliferator-activated receptor gamma, resulting in reverse cholesterol transport.

Sanlúcar de Barrameda (Spanish pronunciation: [sanˈlukaɾ ðe βaraˈmeða]), or simply Sanlúcar, is a city in the northwest of Cádiz province, part of the autonomous community of Andalucía in southern Spain. Sanlúcar is located on the left bank at the mouth of the Guadalquivir River opposite the Doñana National Park, 52 km from the provincial capital Cádiz and 119 km from Sevilla, capital of the autonomous region Andalucía. Its population is 68,656 inhabitants (National Institute of Statistics 2019). Sanlúcar has been inhabited since ancient times, and is assumed to have belonged to the realm of the Tartessian civilization. The town of San Lucar was granted to the Spanish nobleman Alonso Pérez de Guzmán in 1297. Its strategic location made the city a starting point for the exploration, colonization and evangelization of America between the 15th and 17th centuries. Sanlúcar lost much of its strategic value after 1645 because of the disgrace of the House of Medina Sidonia, the general decline of Spain under Charles II, the relocation of the Casa de Contratación to the town of Cadiz in 1717, and the Lisbon earthquake of 1755. In the 19th century the economy of the city was converted to viticulture and summer tourism. The 20th century brought destruction and political upheaval as it did elsewhere in Spain during the Spanish Civil War. Sanlúcar was declared a Cultural Historical-artistic site in 1973. Since the restoration of democracy (1975–1982) its town council has borrowed heavily, making Sanlúcar the city with the lowest per capita income in Spain.

Sources: en.wikipedia.org

Frequently asked questions

Does this compound occur naturally in the body?

No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.

What does the abbreviation DAC refer to?

DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.

Why do different sources report different half-lives for the same name?

Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.

How long does the albumin-binding form remain active?

Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.

Network